PMID- 22988526
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20120919
LR  - 20211021
IS  - 2090-567X (Electronic)
IS  - 2090-5661 (Print)
IS  - 2090-5661 (Linking)
VI  - 2012
DP  - 2012
TI  - Primary gastric lymphoma: conservative treatment modality is not inferior to 
      surgery for early-stage disease.
PG  - 951816
LID - 10.5402/2012/951816 [doi]
LID - 951816
AB  - Objectives. The aim of this study was to evaluate clinical characteristics, 
      prognostic factors, survival rates, and treatment modalities in patients with 
      primary gastric lymphoma (PGL). Methods. We retrospectively reviewed and analyzed 
      data from patients treated for PGL in our clinic from 1998 through 2010. Staging 
      was performed using the Lugano Staging System. Overall and disease-free survival 
      (OS and DFS) were calculated from the date of diagnosis. Results. We identified 
      79 patients. Thirty-seven patients (47%) were male. The median age at 
      presentation was 57 (18-85) years. The median follow-up time was 41 (9-52) 
      months. Thirty patients (38%) underwent surgery, 74 (92%) received chemotherapy, 
      and 18 (23%) received radiotherapy. The five-year OS and DFS rates were 91.2% and 
      83.9%, respectively, in patients with stage I/II or IIE disease and 70.6% and 
      65.5%, respectively, in patients with stage IV disease (P = 0.02 for both rates). 
      Treatment modality (surgical or conservative) had no impact on OS or DFS in early 
      stages. In a multivariate analysis, poor performance status, advanced stage, and 
      high LDH levels were significant bad prognostic factors for DFS, while advanced 
      stage, poor performance status, and age > 60 years were significant bad 
      prognostic factors for OS. Conclusion. Surgery provides no advantage for survival 
      over conservative treatment; thus, conservative treatment modalities should be 
      preferred initially at early stages of PGL.
FAU - Selcukbiricik, Fatih
AU  - Selcukbiricik F
AD  - Division of Medical Oncology, Department of Internal Medicine, Cerrahpasa Medical 
      Faculty, Istanbul University, 34098 Istanbul, Turkey.
FAU - Tural, Deniz
AU  - Tural D
FAU - Elicin, Olgun
AU  - Elicin O
FAU - Berk, Selin
AU  - Berk S
FAU - Ozguroglu, Mustafa
AU  - Ozguroglu M
FAU - Bese, Nuran
AU  - Bese N
FAU - Ferhanoglu, Burhan
AU  - Ferhanoglu B
LA  - eng
PT  - Journal Article
DEP - 20120829
PL  - Egypt
TA  - ISRN Oncol
JT  - ISRN oncology
JID - 101567026
PMC - PMC3437657
EDAT- 2012/09/19 06:00
MHDA- 2012/09/19 06:01
PMCR- 2012/08/29
CRDT- 2012/09/19 06:00
PHST- 2012/07/10 00:00 [received]
PHST- 2012/07/27 00:00 [accepted]
PHST- 2012/09/19 06:00 [entrez]
PHST- 2012/09/19 06:00 [pubmed]
PHST- 2012/09/19 06:01 [medline]
PHST- 2012/08/29 00:00 [pmc-release]
AID - 10.5402/2012/951816 [doi]
PST - ppublish
SO  - ISRN Oncol. 2012;2012:951816. doi: 10.5402/2012/951816. Epub 2012 Aug 29.